Grants and Contracts Details
Ewing sarcoma is bone and soft tissue cancer diagnosed predominantly in children and young adults. Over 30% of the children who are diagnosed with the disease do not survive and this occurs more often among teenagers. Here we propose to take the next step, based on our previous research efforts, and develop a new drug that is selectively toxic to Ewing sarcoma tumors. This project is relevant to public health, because it aims to complete specific studies required for the submission of an investigational new drug application, which is required prior to testing a molecule in the clinic. This is a high-risk, high-reward project and once completed, we expect to have made significant progress toward developing a new potent and selective medication to treat children with Ewing sarcoma.
|Effective start/end date||7/1/20 → 6/30/21|
- KY Cabinet for Health and Family Services: $365,979.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.